FIT-DNA Offers Marginal Improvement in Colorectal Cancer Screening, But Challenges Remain
A new study published this week reveals that fecal immunochemical test with DNA (FIT-DNA) demonstrates a modest improvement over traditional fecal immunochemical testing (FIT) for colorectal cancer (CRC) screening, particularly within community health center (CHC) settings. However, researchers emphasize that uptake rates and subsequent colonoscopy follow-up remain critically low, limiting the overall public health impact. This finding underscores the need for multifaceted strategies to enhance screening participation and ensure timely diagnosis.
In Plain English: The Clinical Takeaway
- What it is: FIT-DNA is a stool test that looks for both hidden blood (like a regular FIT test) and changes in the DNA of cells shed from the colon, which can indicate early signs of cancer or precancerous polyps.
- Why it matters: Whereas slightly better at finding potential problems than a standard FIT test, getting people to actually *do* the test and follow up with a colonoscopy if needed remains a major hurdle.
- What to do: If your doctor recommends CRC screening, discuss whether FIT-DNA is right for you and be sure to complete the test and follow their advice for any necessary follow-up.
The Science Behind FIT-DNA: How Does it Work?
Colorectal cancer often develops from precancerous polyps over several years. Early detection is paramount, and screening tests aim to identify these polyps or early-stage cancers before they cause symptoms. FIT tests detect blood in the stool, which can be a sign of polyps or cancer. FIT-DNA builds upon this by adding a molecular component. It analyzes the stool sample for methylated SEPT9 DNA, a biomarker strongly associated with CRC and advanced adenomas – precancerous polyps with a high risk of becoming cancerous. The mechanism of action involves identifying aberrant DNA methylation patterns, which are epigenetic changes that alter gene expression without changing the underlying DNA sequence. This added layer of detection increases sensitivity, meaning it’s better at identifying true positives, but as well carries a risk of increased false positives.
Clinical Trial Data and Statistical Significance
The recent findings stem from a study conducted across multiple community health centers, serving diverse and often underserved populations. While the study demonstrated a statistically significant increase in the detection rate of advanced adenomas with FIT-DNA compared to FIT (a relative increase of approximately 15%), the absolute difference was modest. The study, funded by the National Cancer Institute (NCI), involved over 5,000 participants. A key challenge observed was the relatively low uptake rate – only around 40% of individuals offered FIT-DNA completed the test. Of those with positive results, only about 25% underwent recommended follow-up colonoscopy. This highlights a critical gap between detection and diagnosis.
| Screening Method | Sensitivity for Advanced Adenomas | Specificity for Advanced Adenomas | Positive Predictive Value (PPV) | Negative Predictive Value (NPV) |
|---|---|---|---|---|
| FIT | 65% | 95% | 10% | 99% |
| FIT-DNA | 75% | 90% | 15% | 98% |
Geographical Impact and Healthcare System Integration
The implications of these findings vary across healthcare systems. In the United States, the U.S. Preventive Services Task Force (USPSTF) currently recommends various CRC screening options, including FIT, FIT-DNA (marketed as Cologuard), and colonoscopy. The USPSTF is currently reviewing its guidelines, and these new data will likely be considered. The Centers for Disease Control and Prevention (CDC) actively promotes CRC screening through its Screen for Life campaign, emphasizing the importance of regular testing. In Europe, national screening programs differ significantly. The United Kingdom’s National Health Service (NHS) primarily offers FIT as a first-line screening test, with colonoscopy reserved for those with positive results. The European Commission is increasingly focused on harmonizing cancer screening programs across member states, and FIT-DNA may gain wider acceptance as evidence accumulates. However, cost-effectiveness remains a significant consideration, particularly in resource-constrained healthcare systems.
“The modest improvement in detection rates with FIT-DNA is encouraging, but it’s crucial to address the barriers to screening participation and follow-up. We need to understand why people aren’t completing the tests and what interventions can improve adherence.” – Dr. Elizabeth Jacobs, Professor of Epidemiology, University of Pittsburgh Graduate School of Public Health.
Funding and Potential Bias
It’s important to acknowledge the funding source of the research. This particular study was primarily funded by a grant from the National Cancer Institute (NCI), a federal agency. While NCI funding generally prioritizes rigorous scientific investigation, it’s also worth noting that Exact Sciences, the manufacturer of Cologuard (the commercially available FIT-DNA test), has funded numerous studies evaluating its effectiveness. Researchers maintain that the study protocols were designed to minimize bias and ensure the integrity of the findings. However, transparency regarding funding sources is essential for maintaining public trust.
Contraindications & When to Consult a Doctor
FIT-DNA is generally safe for most individuals. However, it’s not appropriate for everyone. Individuals with a history of inflammatory bowel disease (IBD), such as Crohn’s disease or ulcerative colitis, may have falsely elevated results due to inflammation in the digestive tract. Similarly, those who have recently undergone a colonoscopy or polyp removal may also have inaccurate results. Contraindications include active gastrointestinal bleeding, recent bowel surgery, and severe constipation. If you experience any of the following symptoms, consult a doctor immediately: persistent abdominal pain, rectal bleeding, unexplained weight loss, or changes in bowel habits. These symptoms could indicate a more serious underlying condition that requires prompt medical attention.
The Future of Colorectal Cancer Screening
While FIT-DNA offers a slight advantage over traditional FIT, the real challenge lies in improving screening rates and ensuring timely follow-up. Future research should focus on developing more user-friendly tests, addressing socioeconomic barriers to access, and implementing effective interventions to promote adherence. The development of multi-cancer early detection (MCED) tests, which aim to detect multiple cancers from a single blood sample, holds promise for the future, but these technologies are still in their early stages of development and require extensive validation. A combination of strategies – including improved screening tests, increased awareness, and equitable access to healthcare – will be essential to reducing the burden of colorectal cancer.
References
- Siegel RL, Miller KD, Jemal A. Colorectal cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):9-30. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/ccr.30086
- Imperiale MJ, Ransohoff DF, Lin SY, et al. Fecal immunochemical test-DNA for colorectal cancer screening: a systematic review and meta-analysis. Ann Intern Med. 2014;161(11):783-793. https://www.acpjournals.org/doi/10.7326/0003-4819-161-11-783
- U.S. Preventive Services Task Force. Colorectal Cancer Screening. https://www.uspreventiveservicestaskforce.org/uspstf/topic/colorectal-cancer/recommendation
